期刊
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
卷 10, 期 1, 页码 63-73出版社
ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
DOI: 10.1097/APO.0000000000000371
关键词
biologic; drug; immunomodulation; uveitis
The management of noninfectious uveitis is entering a new era with the use of biologic drugs targeting inflammation at the molecular level, aiming to achieve specific immunomodulation with a low rate of serious adverse events.
The management of noninfectious uveitis is constantly evolving. A new biologic era in treatment began after the effectiveness of tumor necrosis factor-alpha blocking drugs was demonstrated in rheumatologic inflammatory diseases. The goal of specific immunomodulation with a biologic drug is to target inflammation at the molecular level with a low rate of serious adverse events. The purpose of this review is to summarize current knowledge of biologic drugs in the treatment of noninfectious uveitis by describing clinical studies and recent pharmacological developments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据